Literature DB >> 20209604

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Mustafa S Ascha1, Ibrahim A Hanouneh, Rocio Lopez, Tarek Abu-Rajab Tamimi, Ariel F Feldstein, Nizar N Zein.   

Abstract

UNLABELLED: Nonalcoholic steatohepatitis (NASH) is a well-recognized cause of cirrhosis and has been increasingly associated with the development of hepatocellular carcinoma (HCC). The aims of this study were to (1) estimate the incidence of HCC in patients with NASH-related cirrhosis, (2) compare incidence in NASH-related cirrhosis with hepatitis C virus (HCV)-related cirrhosis, and (3) identify risk factors of HCC in patients with NASH-related cirrhosis compared with HCV-related cirrhosis. Adult patients with cirrhosis secondary to chronic HCV (n = 315) or NASH (n = 195) were evaluated at our hepatobiliary clinic between 2003 and 2007. To assess for HCC development, all patients were monitored using serial abdominal computed tomography and serum alpha-fetoprotein every 6 months. Kaplan-Meier analysis was performed to estimate the cumulative incidence of HCC. Descriptive statistics were computed for all factors. Univariate and multivariate Cox regression analysis were used to assess associations between HCC and factors of interest. The median follow-up was 3.2 years (25th percentile [P25], 75th percentile [P75]: 1.7, 5.7) during which 25/195 (12.8%) of NASH-cirrhotic and 64/315 (20.3 %) of HCV-cirrhotic patients developed HCC (P = 0.03). Yearly cumulative incidence of HCC was found to be 2.6% in patients with NASH-cirrhosis, compared with 4.0% in patients with HCV cirrhosis (P = 0.09). Multivariate regression analysis revealed that older age (P = 0.006) and alcohol consumption (P = 0.002) were independent variables associated with development of HCC in patients with NASH-cirrhosis. Compared with nondrinkers, patients who reported any regular alcohol consumption were at greater risk for HCC development (hazard ratio: 3.6; P25, P75: 1.5, 8.3).
CONCLUSION: Patients with NASH cirrhosis have a greatly increased risk of liver cancer. Alcohol consumption, a modifiable risk factor, appears to be the most significant factor associated with risk of HCC development in our study population.

Entities:  

Mesh:

Year:  2010        PMID: 20209604     DOI: 10.1002/hep.23527

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  404 in total

1.  Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease.

Authors:  James Philip Esteban; Amreen Dinani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-03

2.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Outcomes of Bariatric Surgery in Patients with Cirrhosis.

Authors:  Inka Miñambres; Miguel Angel Rubio; Ana de Hollanda; Irene Breton; Nuria Vilarrasa; Silvia Pellitero; Marta Bueno; Albert Lecube; Clara Marcuello; Albert Goday; Maria D Ballesteros; German Soriano; Assumpta Caixàs
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

4.  Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis.

Authors:  Shogo Tanaka; Yuji Iimuro; Tadamichi Hirano; Seikan Hai; Kazuhiro Suzumura; Ikuo Nakamura; Yuichi Kondo; Jiro Fujimoto
Journal:  Surg Today       Date:  2013-08-31       Impact factor: 2.549

5.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

6.  Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

Authors:  Shingo Tanaka; Koji Miyanishi; Masayoshi Kobune; Yutaka Kawano; Toshifumi Hoki; Tomohiro Kubo; Tsuyoshi Hayashi; Tsutomu Sato; Yasushi Sato; Rishu Takimoto; Junji Kato
Journal:  J Gastroenterol       Date:  2013-01-19       Impact factor: 7.527

7.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

8.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.

Authors:  Thomas Klein; Masato Fujii; Jan Sandel; Yuichiro Shibazaki; Kyoko Wakamatsu; Michael Mark; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-09-19       Impact factor: 2.309

9.  Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.

Authors:  Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; Jorge A Marrero; Katharine McCallister; Hannah Fullington; Caroline Mejias; Akbar K Waljee; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm
Journal:  Hepatology       Date:  2018-12-14       Impact factor: 17.425

10.  Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda; Toshifumi Wakai; Masayuki Kubota; Mami Osawa; Yuki Hirose; Jun Sakata; Takashi Kobayashi; Shun Fujimaki; Masaaki Takamura; Satoshi Yamagiwa; Yutaka Aoyagi
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.